Publications by authors named "Severine Danmadji Nadlaou"
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).
BMC Med
November 2024
Article Synopsis
- The study investigated the effectiveness and safety of the rVSV-ZEBOV vaccine against Zaire Ebolavirus disease among contacts of EVD survivors, focusing on the influence of pre-existing immunity on vaccination outcomes.
- Ten percent of participants had pre-existing antibodies, but both those with and without antibodies showed significant increases in IgG levels post-vaccination, indicating strong immune responses.
- The findings support the vaccine's safety and suggest that pre-vaccination antibody screening is unnecessary, as it does not negatively impact the immune response to the vaccine.
Transmission trees can be established through detailed contact histories, statistical or phylogenetic inference, or a combination of methods. Each approach has its limitations, and the extent to which they succeed in revealing a 'true' transmission history remains unclear. In this study, we compared the transmission trees obtained through contact tracing investigations and various inference methods to identify the contribution and value of each approach.
View Article and Find Full Text PDFUnderstanding risk factors for Ebola transmission is key for effective prediction and design of interventions. We used data on 860 cases in 129 chains of transmission from the latter half of the 2013-2016 Ebola epidemic in Guinea. Using negative binomial regression, we determined characteristics associated with the number of secondary cases resulting from each infected individual.
View Article and Find Full Text PDFRing vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
Lancet Infect Dis
December 2017
Background: In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting.
Methods: Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities.